Actively Recruiting
A Study of MHB048C in Patients With Advanced Solid Tumors
Led by Minghui Pharmaceutical (Hangzhou) Ltd · Updated on 2026-04-09
200
Participants Needed
1
Research Sites
193 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB048C monotherapy.
CONDITIONS
Official Title
A Study of MHB048C in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agrees to participate in the study and signs the informed consent form.
- Age 2 18 years, no restriction on gender.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Estimated life expectancy 2 3 months.
- Histologically or cytologically confirmed advanced solid tumors that are refractory to standard therapy, intolerant to standard therapy, or have no standard treatment options.
- At least one measurable lesion per RECIST v1.1 criteria or one bone.
- Adequate bone marrow reserve and organ function.
You will not qualify if you...
- History of 2 primary malignancies within 5 years prior to informed consent.
- Received chemotherapy within 3 weeks, radiotherapy within 4 weeks, or biologic, endocrine, or immunotherapy within 4 weeks before first study dose.
- Medication of other unmarketed investigational drugs or therapies within 4 weeks before the first dose of investigational drug.
- Brain metastases, bone marrow metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.
- Severe bone damage caused by bone metastasis of prostate cancer.
- Has adverse reactions from previous anti-tumor treatment that have not recovered to 2 CTCAE 5.0 Grade 1.
- Severe lung disease affecting pulmonary function.
- Vaccinated within 4 weeks before dosing.
- Active systemic infection requiring treatment within 7 days before dosing.
- Serious cardiovascular or cerebrovascular diseases.
- Uncontrolled third-space effusions not suitable for enrollment.
- Significant bleeding, bleeding tendency, or non-healing wounds within 1 month before first dose.
- Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
- Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.
- Known alcohol or drug dependence.
- Pregnant or breastfeeding women, or individuals planning to conceive.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
C
CMO/ Senior Vice President of R&D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here